More NIH Virtual Lockdowns for Grant Appraisals
Published Date: 9/24/2025
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings on November 4-5, 2025, to review and decide on important grant applications. These meetings affect researchers and small businesses seeking funding for projects in drug discovery, cell biology, and cancer research. No public access is allowed to protect private info and trade secrets, but these reviews help decide where government research money goes.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Small Businesses: Confidential NIH Grant Reviews
If you are a small business seeking NIH funding for areas like assay development, drug discovery tools, or imaging, your grant applications will be reviewed in closed virtual meetings on November 4-5, 2025. The meetings are closed to protect confidential trade secrets and commercial information, which helps keep your proprietary data private during review.
Researchers and Fellows: Closed Review of Fellowship Grants
If you are a researcher or fellowship applicant in fields like cell biology, developmental biology, bioengineering, oncology, or Alzheimer’s research, your grant or fellowship applications will be reviewed in closed virtual meetings on November 4-6, 2025. These closed sessions protect personal information about applicants and the confidential contents of applications while deciding which projects receive NIH funding.
Public Access: No Attendance Allowed
The listed NIH review meetings on November 4-6, 2025 will be closed to the public and held virtually, so members of the public cannot attend or observe the grant discussions. The closure is to prevent disclosure of trade secrets and personal information, meaning the public will not have direct access to these deliberations about where government research funds are awarded.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-18513, Notice of Public Meeting of the Georgia Advisory Committee to the U.S. Commission on Civil Rights
The Georgia Advisory Committee to the U.S. Commission on Civil Rights is holding a public Zoom meeting to review the first draft of their civil rights proposal. This meeting affects anyone interested in civil rights progress in Georgia and invites public attention before final decisions. No money changes are involved, but the timing is key to shaping future civil rights actions.
Next: 2025-18517, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2025 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers and small businesses applying for grants should note these dates as they impact who gets money for cool science work.